Home › Arthralgia › NCT05816226
Topical Treatment for TMJ Arthralgia
Comparison of Topical 1% Diclofenac and Topical 2.5% Hydrocortisone for TMJ Arthralgia
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Arthralgia of at least 1 TMJ for at least 3 days Exclusion Criteria: * Systemic pain condition * Past adverse reaction to steroid * Currently taking steroid * Taken steroid in the past \_\_\_ months * Muscle relaxants (may start after study is complete) * New night guard during study, or within 1 month of start of study (may start after study is complete)
About the study
The goal of this clinical trial is to evaluate the efficacy of topical 2.5% hydrocortisone in TMJ arthralgia. The main questions it aims to answer are:
* How does pain reduction compare? * How does improvement in jaw function limitation compare? * How do side effects compare? Participants will * On day 1 be examined and report their pain level and jaw function limitation * On days 1-21, apply their cream four times a day * On day 21, report their pain level, jaw function limitation, compliance with instructions, and side effects.
Researchers will compare topical 2.5% hydrocortisone and topical 1% diclofenac to see if efficacy and side effects differ.
What is being tested
- Hydrocortisone 2.5% (drug)
- Diclofenac 1% topical (drug)
Sponsor: University of the Pacific · Participants: 90 · Started: Jun 1, 2023
Contact the study team
- Andrew Young, DDS, MSD · Phone: 4153517126
Official record on ClinicalTrials.gov — NCT05816226
Locations in the U.S.
| California | Arthur A. Dugoni School of Dentistry, University of the Pacific, San Francisco |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.